Меню
Набор скоро начнётся NCT07177963

CPET-based HIIT for MAFLD

Без фазы С лечением Metabolic Dysfunction-Associated Fatty Liver Disease

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: HIIT, No specific exercise intervention..
Кому может быть актуально
Состояния в реестре: Metabolic Dysfunction-Associated Fatty Liver Disease. Базовые параметры: 35 лет — 65 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Cardiopulmonary Exercise Testing-based High-intensity Interval Training For Improving MAFLD

Обзор

High-intensity interval training (HIIT), as an individualized exercise training mode based on cardiopulmonary exercise testing (CPET), is characterized by high-intensity training sessions interspersed with short rest periods. The findings from recent trials suggest that in the management of metabolic dysfunction-associated fatty liver disease (MAFLD), compared with traditional aerobic exercise modes such as moderate-intensity continuous training, HIIT may achieve similar or even better effects in reducing liver fat content, increasing peak oxygen uptake, improving insulin resistance, and lowering blood pressure, despite requiring less time commitment and lower energy expenditure. However, there is currently no consensus regarding the formulation of HIIT exercise protocols. Based on the lower limits of the current mainstream HIIT intensity, sets, and interval time parameters, this study aims to assess the effectiveness, safety, and feasibility of the current exercise prescription in improving MAFLD.

Подробное описание

54 Participants aged 35-65 years with MAFLD will be randomized 1:1 to intervention or control. The intervention group will undertake home-based HIIT four times weekly for 8 weeks. Each session comprises 8 cycles with 30-second bouts at 80% peak VO₂ followed by 60-second recoveries at 50% peak VO₂. The control group do not take any types of exercise interventions. Standard care would be provided for both groups.

Вмешательства

  • Поведенческое HIIT
    Exercise sessions were conducted as telemedically supervised, home-based HIIT performed on electric resistance bikes, with protocols individually tailored. Each HIIT session comprised 8 cycles of alternating 30-second high-intensity intervals (HIT at 80% peakVO₂) and 60-second low-intensity recovery intervals (LIT at 50% peakVO₂). Warm-up and cool-down phases were performed with the bike's resistance set to 0 watts (unloaded pedaling). The total intervention duration was 8 weeks. Received health
  • Поведенческое No specific exercise intervention.
    The control group will not receive any exercise intervention, and they will be instructed to not take any structured exercise regimens.Received health lifestyle education based on the Prevention and Treatment Guidelines for Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition) and the Dietary Guidelines for Adults with Hyperlipidemia (2023 Edition).Wear smart bracelets 24/7 to monitor daily activity levels, with participants prohibited from engaging in any other systematic exercise traini

Первичные конечные точки

  • Liver fat content (%) [Срок оценки: Baseline (week 0) , after complete post-training (week 8).]
Вторичные конечные точки (12)
  • LSM (kPa) [Срок оценки: Baseline (week 0) , after complete post-training (week 8).]
  • Blood specimen [Срок оценки: Baseline (week 0) , after complete mid-training (week 4), after complete post-training (week 8).]
  • Blood specimen [Срок оценки: Baseline (week 0) , after complete mid-training (week 4), after complete post-training (week 8).]
  • Blood specimen [Срок оценки: Baseline (week 0) , after complete mid-training (week 4), after complete post-training (week 8).]
  • Blood specimen [Срок оценки: Baseline (week 0) , after complete mid-training (week 4), after complete post-training (week 8).]
  • Blood specimen [Срок оценки: Baseline (week 0) , after complete mid-training (week 4), after complete post-training (week 8).]
  • Blood specimen [Срок оценки: Baseline (week 0) , after complete mid-training (week 4), after complete post-training (week 8).]
  • Blood specimen [Срок оценки: Baseline (week 0) , after complete mid-training (week 4), after complete post-training (week 8).]
  • Blood specimen [Срок оценки: Baseline (week 0) , after complete mid-training (week 4), after complete post-training (week 8).]
  • Blood specimen [Срок оценки: Baseline (week 0) , after complete mid-training (week 4), after complete post-training (week 8).]
  • Blood specimen [Срок оценки: After first time and complete of mid-training (week 4), after first time and complete of post-training (week 8).]
  • Exercise Feasibility [Срок оценки: Every week after complete training from week 1 to week 8.]

Критерии участия

Критерии включения

Adults age 35\~65 years Nonalcoholic fatty liver diagnosed by abdominal ultrasonography

In conjunction with at least one cardiometabolic risk factor:

  • Overweight or Obesity: ≥ 24kg/m2,or waist circumference ≥ 90 cm in men and > 85 cm in women, or excessive body fat mass
  • Prediabetes or type 2 diabetes mellitus: HbA1c ≥ 5.7%, or fasting plasma glucose ≥ 6.1mmol/L, or 2-h plasma glucose during OGTT ≥ 7.8mmol/L
  • Plasma triglycerides ≥ 1.7 mmol/L (>-150 mg/dl) or lipid-lowering treatment
  • HDL-cholesterol ≤ -1.0 mmol/L in men and ≤ -1.3 mmol/L in women or lipid-lowering treatment
  • Blood pressure ≥ 130/85 mmHg or treatment for hypertension

Критерии исключения

  • Contraindications for Cardiopulmonary Exercise Testing
  • The electrocardiogram (ECG) results during cardiopulmonary exercise testing (CPET) showed positive findings
  • Receiving GLP-1 receptor agonists, SGLT-2i, or taking >2 antihypertensive/hypoglycemic/lipid-lowering/ antiarrhythmic drugs
  • Taking dietary supplements (e.g., fish oil products, over-the-counter diet pills, meal replacements)
  • Mental illness
  • Other liver diseases
  • Movement disorder related diseases and lower limb motor injury in the past 6 months
  • Pregnant, lactating or planning to become pregnant in the near future

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Лечение

Центры проведения

Китай · 5 центров
  • Beijing Ditan Hospital, Capital Medical University — Пекин
  • Beijing Friendship Hospital, Capital Medical University — Пекин
  • Beijing Youan Hospital, Capital Medical University — Пекин
  • Peking University Third Hospital — Пекин
  • The Fifth Medical Center, Chinese PLA General Hospital — Пекин

Идентификаторы

NCT: NCT07177963 · CPHIT1

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗